Echinacea
The name “echinacea” mainly refers to Echinacea purpurea, Echinacea angustifolia, and Echinacea pallida. The extracts contain classes of molecules (alkylamides, caffeic acid derivatives such as echinacoside/cichoric acid, polysaccharides) that may modulate innate immune and inflammatory responses. In the gut–immunity field, interest concerns the mucosal axis and airway immunity, but the quality of the evidence varies and results are not always reproducible across different products.
Immunomodulatory phytocompound with evidence mainly for the prevention/reduction in duration of respiratory infections; data are heterogeneous and dependent on the species and extract
The name “echinacea” mainly refers to Echinacea purpurea, Echinacea angustifolia, and Echinacea pallida. The extracts contain classes of molecules (alkamides, caffeic acid derivatives such as echinacoside/cichoric acid, polysaccharides) that may modulate innate immune and inflammatory responses. In the gut–immunity field, interest concerns the mucosal axis and airway immunity, but the quality of the evidence varies and results are not always reproducible across different products.
Mechanism of action
Proposed mechanisms (depending on the phytocomplex and the experimental model): (1) Modulation of innate immunity: modulation of cytokines (e.g. IL-1β, IL-6, TNF-α) and pattern recognition signals (e.g. TLRs), with effects that may be either pro- or anti-inflammatory depending on the context; (2) Activity on immune cells: effects on phagocytosis, macrophage activity, and NK cells reported in in vitro/ex vivo studies; (3) Alkamides as ligands of cannabinoid receptors (especially CB2) with potential immunomodulatory and anti-inflammatory effects; (4) Local mucosal effects: polysaccharides and unabsorbed components may interact with the mucosa and the microbiota, influencing local immune signals; (5) Possible indirect antiviral activity: more plausible through modulation of the host response than through a clinically relevant direct antiviral action.
Supported benefits
- Reduction in the risk of developing the common cold/upper respiratory tract infections in some studies and meta-analyses, with high heterogeneity among preparations (moderate)
- Reduction in the duration and/or severity of cold symptoms in some trials, especially when taken early; results are not consistent across products (moderate)
- Support for mucosal immunity (gut–immunity hypothesis) and modulation of inflammatory markers: direct clinical evidence is limited and inconclusive (limited)
Safety & side effects
- Gastrointestinal disturbances (nausea, abdominal pain, diarrhea) in a minority of subjects
- Headache or dizziness (non-specific reports)
- Allergic reactions: rash, itching, hives; more significant reactions are rare, especially in subjects allergic to Asteraceae
- Unpleasant taste or oral irritation with some formulations
FAQ
Does echinacea “work” for the common cold?
Meta-analyses and trials show a possible benefit on the risk and/or duration of symptoms, but results are heterogeneous. The difference between species, plant part, and extract standardization is a determining factor: not all products are equivalent.
Does it have a role in gut health and immunity?
The biological rationale concerns mucosal immunity and the modulation of inflammatory mediators; however, specific clinical evidence on intestinal outcomes (e.g. GI symptoms, mucosal biomarkers) is still limited compared with studies on respiratory infections.
Is E. purpurea or E. angustifolia better?
It depends on the extract and the indication studied. E. purpurea is often used for aerial parts/juice and is widely represented in common cold trials; E. angustifolia is often used as root. Without standardization and clinical data on the specific product, it is not possible to establish overall superiority.
Can it be used long term?
Many studies are of limited duration (weeks for prevention, days for treatment). For longer periods, the evidence on safety/effectiveness is less robust, so caution and professional evaluation are important in cases of prolonged use.
What is the main risk?
Allergic reactions (especially in subjects allergic to Asteraceae) and the uncertainty linked to product variability. In autoimmune conditions or with immunosuppression, immunomodulation may be problematic.
The information provided is for informational and educational purposes only. It does not constitute medical advice. Use must be assessed and authorized by a qualified healthcare professional.
Mechanism of action
Proposed mechanisms (depending on the phytocomplex and the experimental model): (1) Modulation of innate immunity: modulation of cytokines (e.g. IL-1β, IL-6, TNF-α) and pattern recognition signals (e.g. TLR) with effects that may be either pro- or anti-inflammatory depending on the context; (2) Activity on immune cells: effects on phagocytosis, macrophage activity, and NK cells reported in in vitro/ex vivo studies; (3) Alkylamides as ligands of cannabinoid receptors (especially CB2) with potential immunomodulatory and anti-inflammatory effects; (4) Local mucosal effects: polysaccharides and unabsorbed components may interact with the mucosa and microbiota, influencing local immune signals; (5) Possible indirect antiviral activity: more plausibly through modulation of the host response than through a clinically relevant direct antiviral action.
Scientific benefits
Contraindications
- Known allergy to Echinacea or other Asteraceae/Compositae (e.g. ragweed, daisies, chrysanthemums) due to increased risk of allergic reactions
- Autoimmune diseases or conditions in which immunomodulation may be undesirable: specialist evaluation required
- Organ transplant or immunosuppressive therapy: potential interference with the therapeutic goal (immunosuppression)
- Pregnancy and breastfeeding: overall data are inconclusive; caution and professional evaluation advised
- Pediatric age: evidence and safety depend on age and formulation; professional evaluation required
Side effects
- Gastrointestinal disorders (nausea, abdominal pain, diarrhea) in a minority of subjects
- Headache or dizziness (non-specific reports)
- Allergic reactions: rash, itching, hives; rarely more serious reactions, especially in subjects allergic to Asteraceae
- Unpleasant taste or oral irritation with some formulations
Interactions
- Immunosuppressants (e.g. cyclosporine, tacrolimus, systemic corticosteroids, biologics): possible functional antagonism or alteration of the immune response; clinical relevance is not always predictable
- Drugs metabolized by CYP: some components may modulate enzymes/transporters in vitro; the clinical impact is generally considered low but not zero, especially with concentrated extracts and polytherapy
- Anticoagulants/antiplatelet agents: direct evidence is limited; caution due to possible individual variations and the presence of comorbidities/infections
- Other “immunostimulant” products: possible increase in immune-mediated adverse effects in predisposed subjects
Regulatory status
In the EU and in other countries it is commonly marketed as a food supplement or traditional herbal medicinal product, with indications/claims regulated at the national or supranational level. Specific claims regarding the prevention/treatment of infectious diseases are generally limited or not permitted for supplements.
Supplements and peptides
Gut and Immune SystemBovine colostrum
Bovine colostrum is the secretion produced by the cow in the first hours/days after calving, rich in immunoglobulins,…
Gut and Immune SystemLactoferrin
Lactoferrin (LF) is a glycoprotein of the transferrin family, present in mucosal secretions (milk, saliva, tears) and…
Gut and Immune SystemMulti-strain probiotics
Multi-strain probiotics are formulations that combine multiple species and/or strains (e.g. Lactobacillus,…